Impact of Conventional Treatments and Clinical Variables on Thyroid Cancer
THY-CANC
Retrospective and Prospective Evaluation of the Impact of Innovative and Conventional Treatments and of Clinical Variables on the Outcome of Thyroid Cancer
1 other identifier
observational
3,000
1 country
1
Brief Summary
DTC has a generally favorable prognosis. The possibility to discriminate between patients with aggressive tumors and those with a more indolent behavior may reduce the need for unnecessary treatments. Aim of this observational study is to evaluate how anamnestic, clinical, and histopathological variables may influence the outcome of the enrolled patients, both regarding morbidity and mortality and in terms of therapeutic choices. The study aims to evaluate the prognostic impact of the therapeutic interventions in terms of efficacy and regarding the appearance of adverse events.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jul 2022
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 12, 2022
CompletedFirst Submitted
Initial submission to the registry
February 17, 2023
CompletedFirst Posted
Study publicly available on registry
March 2, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 8, 2032
ExpectedStudy Completion
Last participant's last visit for all outcomes
March 8, 2042
August 3, 2025
August 1, 2025
9.7 years
February 17, 2023
August 1, 2025
Conditions
Outcome Measures
Primary Outcomes (9)
Dynamic risk stratification
impact of the different variables on the DRS
one year from the primary treatment
Dynamic risk stratification
impact of the different variables on the DRS
five years from the primary treatment
Dynamic risk stratification
impact of the different variables on the DRS
ten years from the primary treatment
Progression-free survival
impact of the different variables on the PFS in patients treated with TKI for advanced thyroid cancer
one year from the primary treatment
Progression-free survival
impact of the different variables on the PFS in patients treated with TKI for advanced thyroid cancer
five years from the primary treatment
Progression-free survival
impact of the different variables on the PFS in patients treated with TKI for advanced thyroid cancer
ten years from the primary treatment
Overall survival
impact of the different variables on the OS in patients treated with TKI for advanced thyroid cancer
one year from the primary treatment
Overall survival
impact of the different variables on the OS in patients treated with TKI for advanced thyroid cancer
five years from the primary treatment
Overall survival
impact of the different variables on the OS in patients treated with TKI for advanced thyroid cancer
ten years from the primary treatment
Eligibility Criteria
all consecutive patients referred to our tertiary clinical center for thyroid cancer
You may qualify if:
- \- thyroid cancer diagnosis
You may not qualify if:
- patients unable to sign informed consent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Istituto Auxologico Italiano, IRCCS
Milan, 20149, Italy
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 17, 2023
First Posted
March 2, 2023
Study Start
July 12, 2022
Primary Completion (Estimated)
March 8, 2032
Study Completion (Estimated)
March 8, 2042
Last Updated
August 3, 2025
Record last verified: 2025-08